Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematopoietic and Lymphatic System Neoplasm 1Graft vs Host Disease 1Cholangiocarcinoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

Gemcitabine 15Cisplatin 13durvalumab 12pembrolizumab 10Oxaliplatin 8Magnetic Resonance Spectroscopy 8Biopsy 7Specimen Handling 6Leucovorin 6Fluorouracil 5Paclitaxel 4Folfox protocol 4futibatinib 3Taxes 3Radiation 3Nivolumab 3Irinotecan 3Immunoglobulin G 3Disulfides 3tislelizumab 2pemigatinib 2olaparib 2lenvatinib 2fludarabine 2dehydroftorafur 2Radiation Dose Hypofractionation 2Platinum 2Liver Transplantation 2Fluorodeoxyglucose F18 2Floxuridine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × axatilimab × 90 days × Clear all
NCT04301778 2026-03-13

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
5 enrolled 13 charts
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡